BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35142188)

  • 1. Comparative Effectiveness of Peg-Asparaginase and L-Asparaginase on Coagulation Markers Among Pediatric Patients with Acute Lymphoblastic Leukemia.
    Zekavat OR; Safari A; Bordbar MR; Haghpanah S; Zareifar S; Shahriari M; Mohammadzadeh M
    Clin Lab; 2022 Feb; 68(2):. PubMed ID: 35142188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different profile of thrombin generation in children with acute lymphoblastic leukaemia treated with native or pegylated asparaginase: A cohort study.
    Rozen L; Noubouossie D; Dedeken L; Huybrechts S; Lê PQ; Ferster A; Demulder A
    Pediatr Blood Cancer; 2017 Feb; 64(2):294-301. PubMed ID: 27605400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study.
    Risseeuw-Appel IM; Dekker I; Hop WC; Hählen K
    Med Pediatr Oncol; 1994; 23(4):335-43. PubMed ID: 8058004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
    Cooperation Group of Phase II Clinical Trial of PEG-Asp
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency.
    Mitchell L; Hoogendoorn H; Giles AR; Vegh P; Andrew M
    Blood; 1994 Jan; 83(2):386-91. PubMed ID: 8286739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
    Mesegué M; Alonso-Saladrigues A; Pérez-Jaume S; Comes-Escoda A; Dapena JL; Faura A; Conde N; Català A; Ruiz-Llobet A; Zapico-Muñiz E; Camós M; Rives S
    Hematol Oncol; 2021 Dec; 39(5):687-696. PubMed ID: 34397119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
    Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
    Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product.
    Matteo C; Colombini A; Bettini LR; Porcu L; Barzaghi S; Ceruti T; Silvestri D; Amoroso A; Dell'Acqua F; Gotti G; Nastasi C; Zucchetti M; Rizzari C
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29753. PubMed ID: 35561075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?
    Lussana F; Minetto P; Ferrara F; Chiaretti S; Specchia G; Bassan R
    BMC Cancer; 2020 Oct; 20(1):956. PubMed ID: 33008391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
    Christ TN; Stock W; Knoebel RW
    J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-asparaginase activity and anti-L-asparaginase antibody as biomarkers in estimating PEG-asp-related anaphylaxis risk in childhood acute lymphoblastic leukemia patients.
    Cui J; Jiang L; Xu B; Bai Y
    Allergol Immunopathol (Madr); 2023; 51(3):28-35. PubMed ID: 37169557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombin III as the Indicator of L-Asparaginase Activity in Children Treated for Acute Lymphoblastic Leukemia.
    Czogała M; Balwierz W; Sztefko K; Rogatko I
    J Pediatr Hematol Oncol; 2017 Mar; 39(2):114-120. PubMed ID: 28060110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of adverse effects associated with pegylated Escherichia coli asparaginase on coagulation in the treatment of patients with NK/T-cell lymphoma.
    Yang J; Guo X; Guo S; Yan H; Chai L; Guo Y; Li Z; Hao Z; Su L
    Medicine (Baltimore); 2022 Mar; 101(10):e25578. PubMed ID: 35451376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
    Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
    Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
    Liu L; Xie XT
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase.
    Chen Y; Buhlinger K; Perissinotti AJ; Schepers AJ; Benitez L; Auten J; Chen SL; Bixby DL; Burke PW; Pettit KM; Marini BL
    Leuk Lymphoma; 2022 Nov; 63(11):2663-2670. PubMed ID: 35699966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase.
    Halton JM; Mitchell LG; Vegh P; Eves M; Andrew ME
    Am J Hematol; 1994 Nov; 47(3):157-61. PubMed ID: 7524313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of a single pegylated asparaginase (PEG-ASP) dose in remission induction for acute lymphoblastic leukemia (ALL).
    Helbig G; Armatys A; Boral K; Kopinska AJ; Wozniczka K; Dworaczek M; Chromik K; Koclega A; Panz-Klapuch M; Wysocka M; Janikowska A
    Neoplasma; 2018 Nov; 65(6):993-997. PubMed ID: 29940768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.
    Chen R; Atenafu EG; Seki J; Liu X; Chan S; Gupta V; Maze D; Shuh AC; Minden MD; Yee K; Schimmer AD; Sibai H
    Br J Haematol; 2023 May; 201(4):645-652. PubMed ID: 36794878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.